Oncology & Hematology

Clinical Research: Phase 1 - Phase 4

Premier Insight 282 | Leveraging the Power of Communication: Supporting Enrollment of a Phase 2 Cervical Cancer Study During a Pandemic

Background Cervical cancer is the fourth most common cancer in women. Despite being highly preventable, over 600,000 women were diagnosed and more than 340,000 died from the disease worldwide in 2020. The majority of cervical cancers are caused by infection with human papillomavirus (HPV) and the implementation of HPV vaccines has been shown to reduce...

Clinical Research: Phase 1 - Phase 4

7 Factors Fueling the Growth of Oncology Trials in Asia-Pacific

Oncology clinical trial activity in the Asia-Pacific (APAC) region has been robust over the past decade, increasing 138 percent from 2010 to 2020.1 In the past, most studies conducted in APAC countries were later studies, but there has recently been an uptick in the number of phase 1 trials. This bustling activity, in combination with...

Clinical Research: Phase 1 - Phase 4

Conducting Successful Oncology Trials in the Asia-Pacific Region

The Asia-Pacific (APAC) region now ranks first in the world for total number of active oncology clinical trials, with China alone accounting for more than half of those studies.1 To take advantage of the potential benefits of conducting clinical research in APAC countries, sponsors need to understand the nuances of designing and operationalizing studies in...

Clinical Research: Phase 1 - Phase 4

Making the Asia-Pacific Region a Destination of Choice for Oncology Clinical Trials

Introduction Over the past decade, the Asia-Pacific (APAC) region has seen the most robust growth in oncology clinical trial activity, with a 138 percent increase over the period from 2010 to 2020. In fact, APAC now ranks first in the world for total number of ongoing oncology clinical trials, with China accounting for more than...

Clinical Research: Phase 1 - Phase 4

Addressing the Challenges and Opportunities in Gynecologic Cancer Research

Gynecologic cancers continue to be a significant cause of female morbidities and mortality worldwide. Significant unmet needs exist in diagnosis and treatment. These cancers are often detected at later stages when therapeutic options are limited, and advanced or recurrent disease leads to a poor prognosis. Earlier diagnosis and more effective treatments will enhance the quality...

Clinical Research: Phase 1 - Phase 4

PM360 | New Developments in Gynecological Cancer Research

Substantial unmet needs exist in the diagnosis and treatment of gynecologic cancers. Often, these tumors are detected in later stages when treatment options are limited, and prognosis is poor. However, the gynecologic cancer space is on the cusp of change. The recent introduction of novel medicines, namely targeted therapies, has improved patient care and outcome....

Clinical Research: Phase 1 - Phase 4

Maximizing Oncology Study Outcomes: Overcoming Enrollment Challenges in a Phase 2 Prostate Cancer Clinical Trial

Prostate cancer (PC) is one of the most commonly diagnosed cancers overall and the most frequently diagnosed cancer in men. The 2018 global estimate of new PC cases exceeded 1.2 million, and more than 350,000 men died from the disease worldwide.1 Over the last decade the emergence of new treatments, combined with better use of...

Clinical Research: Phase 1 - Phase 4

Premier Insight 281: Overcoming Enrollment Challenges in a Phase 2 Prostate Cancer Clinical Trial

Background Prostate cancer (PC) is among the most commonly diagnosed cancers overall, and the most frequently diagnosed cancer in men. The 2018 global estimate of new PC cases exceeded 1.2 million with more than 350,000 deaths worldwide.  Over the last decade, new treatments combined with better use of existing therapies in early-stage disease have transformed...

Clinical Research: Phase 1 - Phase 4

Pharmaceutical Commerce: Empowering Patients in Oncology Trials

Patient engagement is critical to the success of oncology clinical trials, many of which have endpoints that require study participants to be followed for many years to evaluate side effects and long-term survival data. And yet, sponsors often postpone careful consideration of strategies for patient engagement and retention until after the treatment phase of their...

Clinical Research: Phase 1 - Phase 4

The Role of Maintenance Therapy in Gynecologic Cancer Treatment

Advanced ovarian and endometrial carcinomas present the greatest challenge in treating gynecologic cancer and, among the five types of female cancers, are responsible for the most U.S. deaths annually.1 With a combination of surgery, chemotherapy, and radiation; patients can go into remission, but the majority will have a recurrence after several months or years. There...